Plain-English translation of NCT05753930 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medicine called in children ages 1–17 who need kidney transplants but have very high levels of antibodies against donor kidneys. works by temporarily reducing these harmful antibodies so children can receive a kidney transplant from a donor that would normally not be compatible. After the medicine works, children will receive the transplant and be monitored closely to make sure everything goes well.
Many children waiting for kidney transplants have such high levels of donor antibodies that they cannot receive most available kidneys, even from living or deceased donors. This medication could open up transplant options for children who have already tried other treatments without success, giving them a chance at a healthy new kidney.
You likely qualify if…
You likely don't qualify if…
When a kidney becomes available for you, you will receive one infusion of the medication through an IV over 15 minutes within 24 hours before your transplant surgery. After your transplant, you will be hospitalized like any other transplant patient and receive standard anti-rejection medicines. You will be closely monitored for 6 months after transplant, with follow-up visits continuing for up to 5 years to track how well your new kidney is working and to watch for any complications.
AI-generated summary from trial data · Jul 8, 2026 · Not medical advice
Finland
France
Spain
Sweden
United Kingdom